Dr Thomas Duthy, Executive Director of Neurotech said “We thank the Monash HREC for this extension, which provides comfort to our Phase I/II trial participants that they are able to receive NTI164 therapy for an additional 52 weeks above existing approvals. We continue to focus our resources on completing the current Phase II/III ASD trial and remain on track to report the results of our Phase II/III ASD trial in late Q1 CY2024 to early Q2 CY2024.”
NTI Price at posting:
9.7¢ Sentiment: None Disclosure: Not Held
